Skip to main content

GILD

Stock

GILD

Stock
Health Care
Drug Manufacturers - General

Performance overview

GILD Price
Price Chart

Forward-looking statistics

Beta
0.22
Risk
27.28%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees18K
Market cap$80.6B

Fundamentals

Enterprise value$154.1B
Revenue$28.7B
Revenue per employee
Profit margin20.76%
Debt to equity130.79

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$4.76
Dividend per share$3.16
Revenue per share$23.05
Avg trading volume (30 day)$922M
Avg trading volume (10 day)$1B
Put-call ratio

Macro factor sensitivity

Growth+0.8
Credit+1.3
Liquidity-0.3
Inflation-0.5
Commodities+0.5
Interest Rates-0.5

Valuation

Dividend yield2.83%
PEG Ratio15.04
Price to sales4.84
P/E Ratio15.04
Enterprise Value to Revenue5.36
Price to book7.26

Upcoming events

Next earnings dayApril 25, 2025
Next dividend day
Ex. dividend dayJune 13, 2025

News

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research (July 10, 2025)
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Benzinga (July 9, 2025)
Final Trades: Synovus, Nextera Energy, Gilead and the IYF

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television (July 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free